[6-K] GSK plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

GSK plc reported insider acquisitions of American Depositary Shares through automatic dividend reinvestment. On October 14, 2025, ADSs were acquired at $43.9461 per ADS on the New York Stock Exchange, reflecting the reinvestment of dividends paid on October 9, 2025.

Hal Barron acquired 3,186.736 ADSs. James Ford acquired 321.543 ADSs. Shobie Ramakrishnan acquired 387.334 ADSs. Each entry is recorded as a single transaction, with the instrument identified as GSK ADSs (ISIN: US37733W2044).

These transactions are routine dividend reinvestments by directors and senior management and do not reflect an open‑market discretionary purchase program.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$43.9461	3,186.736
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-10-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$43.9461	321.543
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-10-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$43.9461	387.334
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-10-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: October 16, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) disclose in this 6-K?

Insider acquisitions of GSK American Depositary Shares via dividend reinvestment on October 14, 2025 at $43.9461 per ADS.

Which GSK insiders acquired ADSs and how many?

Hal Barron: 3,186.736; James Ford: 321.543; Shobie Ramakrishnan: 387.334.

What was the nature of the transactions for GSK (GSK)?

Acquisitions resulted from the reinvestment of dividends paid on October 9, 2025.

At what price were the GSK ADSs acquired?

Each acquisition was executed at $43.9461 per ADS.

Where were the transactions conducted for GSK ADSs?

On the New York Stock Exchange (XNYS).

What financial instrument is involved in these GSK transactions?

GSK American Depositary Shares (ADSs), ISIN US37733W2044.

Is this a single transaction per insider in the GSK filing?

Yes. Each insider’s entry is noted as N/A (single transaction) for aggregation.